Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of
schizophrenia.

This real-world study finds that patients with BPD are able to trade pills for skills, with substantial reductions in a controversial class of medications.

Antidepressant combinations come up wanting in this meta-analysis, with one possible ray of hope.

This study identifies a common clinical scenario where aripiprazole may trigger psychotic symptoms.

Some providers may be reluctant to treat patients with opioid use disorders with MOUD, especially in a busy primary care setting, fearing that these patients are “too complex.” In this observational study, investigators found that patients on MOUD are not all that different from everyone else.

Barbiturates and benzodiazepines are both commonly used for alcohol detoxification. But how do they compare to one another? Here, researchers found some intriguing benefits of phenobarbital.

Side effects are burdensome to patients, but do they also get in the way of recovery? This study sought to clarify how side effects change over time and whether they impede recovery in major depressive disorder.

SSRIs are often used in PTSD, but it is not clear that they work for all kinds of trauma. Trials of SSRIs are generally positive in women and people with a history of sexual trauma, while trials involving combat-related trauma tend to be negative. The current study aimed to better identify predictors of ­response.

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.